Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Open-Label, Multi-Center, Randomized Study of Anti-CCR4 Monoclonal Antibody KW-0761 (Mogamulizumab) Versus Vorinostat in Subjects With Previously Treated Cutaneous T-Cell Lymphoma

Next Previous
X
Search
Trial Profile

Open-Label, Multi-Center, Randomized Study of Anti-CCR4 Monoclonal Antibody KW-0761 (Mogamulizumab) Versus Vorinostat in Subjects With Previously Treated Cutaneous T-Cell Lymphoma

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 23 Jan 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Mogamulizumab (Primary) ; Vorinostat
  • Indications Cutaneous T-cell lymphoma; Mycosis fungoides; Sezary syndrome
  • Focus Registrational; Therapeutic Use
  • Acronyms MAVORIC
  • Sponsors Kyowa Kirin; Kyowa Kirin International; Kyowa Kirin Pharmaceutical Development

    • Most Recent Events

    • 12 Dec 2023 Results presented at the 65th American Society of Hematology Annual Meeting and Exposition
    • 12 Dec 2023 Results of retrospective, post Hoc analysis of Health-Related Quality of Life in Cutaneous T-Cell Lymphoma, presented at the 65th American Society of Hematology Annual Meeting and Exposition
    • 11 Dec 2023 According to a Kyowa Kirin International media release, company announced health-related quality of life (HRQL) findings from a post hoc analysis of the this trial presented at the 65th annual American Society of Hematology meeting in San Diego, CA

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top